Author: Ravi Shankar

Initial data expected in the first half of 2027

LEXINGTON, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that the first patient was dosed in the Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy (“DMD”).

“Dosing the first patient in our Phase 2 clinical trial of rinvatercept represents an important step in advancing our neuromuscular development strategy, and reflects the progress of our team as we continue to advance Keros’ clinical pipeline,” said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer of Keros. “Rinvatercept is designed to modulate key regulators of muscle and bone biology, and we look forward to generating clinical data to inform its potential to treat patients with DMD.”

“DMD, despite advances in treatment, continues to place a significant burden on patients and their families, and the need for additional options remains high,” said Gina O’Grady, B.H.B., MBChB, Ph.D., pediatric neurologist at Starship Children’s Hospital. “Rinvatercept’s mechanism established in preclinical studies provides a compelling rationale for clinical evaluation in DMD. This trial represents an important opportunity to assess its potential impact across both ambulatory and non-ambulatory patients with DMD.”

About the Rinvatercept Phase 2 Clinical Trial (NCT07704099)

The rinvatercept Phase 2 clinical trial is an open-label, multi-cohort basket clinical trial in patients with DMD. The primary objective of this trial is to assess the safety and tolerability of rinvatercept in late-ambulatory and early non-ambulatory patients with DMD. The key secondary objectives of this trial are to evaluate pharmacokinetics, anti-drug antibodies, body composition and comprehensive functional improvements (skeletal muscle, motor, cardiac and pulmonary).

About Rinvatercept

Rinvatercept is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB that is fused to the portion of the human antibody known as the Fc domain. Rinvatercept is designed to act as a ligand trap and inhibit the biological effects of myostatin and activin A, which are negative regulators of muscle and bone mass and strength, to improve skeletal muscle regeneration, increase muscle size and strength, inhibit and reduce fibrosis, inhibit inflammation, reduce fat accumulation and improve bone health through bone anabolic mechanisms. We are developing rinvatercept for the treatment of DMD and for the treatment of amyotrophic lateral sclerosis (“ALS”).

About Keros Therapeutics, Inc.

Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including skeletal muscle, bone, adipose, heart tissue and blood. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead product candidate, rinvatercept, is being developed for the treatment of DMD and for the treatment of ALS. Keros’ most advanced product candidate, elritercept, is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis.

Cautionary Note Regarding Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “forward,” “potential,” “expect” or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include statements concerning: the expected timing of initial data from the Phase 2 clinical trial of rinvatercept in patients with DMD; the potential benefits of rinvatercept, including its potential impact in ambulatory and non-ambulatory patients with DMD; and the progress and objectives of the Phase 2 clinical trial of rinvatercept in DMD. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Keros’ limited operating history and historical losses; Keros’ ability to raise additional funding to complete the development and any commercialization of its product candidates; Keros’ dependence on the success of its product candidates, rinvatercept and elritercept; that Keros may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Keros’ ability to obtain, maintain and protect its intellectual property; and Keros’ dependence on third parties in connection with manufacturing, clinical trials and preclinical studies.

These and other risks are described more fully in Keros’ filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q, filed with the SEC on August 3, 2026, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Keros undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact:

Justin Frantz
jfrantz@kerostx.com
617-221-6042

DENVER, Sept. 28, 2026 (GLOBE NEWSWIRE) — SHF Holdings, Inc., d/b/a Safe Harbor Financial (“Safe Harbor” or the “Company”) (NASDAQ: SHFS), a leading fintech platform serving the banking, lending, and financial services needs of the regulated cannabis and hemp industries, today announced that its Board of Directors has approved a reverse stock split of the Company’s common stock, par value $0.0001 per share, at a ratio of 1-for-12 (the “Reverse Stock Split”).

The Reverse Stock Split was approved by stockholders at a special meeting of the Company’s stockholders held on November 6, 2025, and is expected to become effective at 12:01 a.m. Eastern Time on September 30, 2026. The Company’s common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Stock Market LLC on September 30, 2026 under the existing ticker symbol “SHFS” with a new CUSIP number of 824430 409.

At the effective time of the Reverse Stock Split, every twelve issued and outstanding shares of the Company’s common stock will be automatically combined into one share of common stock. No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to receive fractional shares will receive a number of shares of common stock as rounded up to the nearest whole share.

About Safe Harbor:

Safe Harbor is a cannabis-exclusive financial platform delivering smarter banking, lending, payments and business services tailored to how the cannabis industry actually operates. As one of the original pioneers of compliant financial operations support and cannabis banking consulting in the U.S., Safe Harbor has assisted in the processing of more than $35 billion in cannabis-related depository funds across 41 states and territories. Through its proprietary Cannabis Banking Solutions™ Platform and network of regulated financial institution partners, Safe Harbor empowers cannabis operators to gain clarity, control and confidence in their financial operations. From daily banking to long-term growth, Safe Harbor provides real solutions and personal support — built exclusively for cannabis. Safe Harbor is a financial technology company, not a bank. Banking services are provided by our partner financial institutions. For more information, visit shfinancial.org.

Cautionary Statement Regarding Forward-Looking Statements:

Certain information contained in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included herein may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. Forward-looking statements may include, but are not limited to, statements with respect to the timing, completion and benefits of the Reverse Stock Split. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “outlook,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in Safe Harbor’s filings with the U.S. Securities and Exchange Commission. Safe Harbor undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

Safe Harbor Investor Relations Contact:

ir@SHFinancial.org

Safe Harbor Media Relations Contact:

safeharbor@kcsa.com

COLUMBUS, Ohio, Sept. 28, 2026 (GLOBE NEWSWIRE) — Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding,” “Core” or the “Company”), today announced the promotion of Michael J. Gayford to Chief Operating Officer (“COO”), effective immediately.

In his expanded role, Mr. Gayford will assume operational responsibility for the Company’s North American operations, and Arnold Alanis, Executive Vice President of Operations in Mexico, will report to him. Gayford will also continue to focus on driving operational excellence, overseeing program management, advancing research and development initiatives, and executing strategic programs designed to accelerate growth and improve operational performance.

Mr. Gayford joined Core Molding Technologies in 2023 and has more than 25 years of manufacturing, engineering, and operational leadership experience. Throughout his tenure at Core, he has played a key role in strengthening operational execution, advancing technology initiatives, and supporting the Company’s strategic transformation.

“I am pleased to announce Mike Gayford’s promotion to Chief Operating Officer,” said Eric Palomaki, President and Chief Executive Officer. “Mike has been instrumental in advancing our operational capabilities and driving meaningful improvements across the organization. His leadership, strategic vision, and commitment to excellence have contributed significantly to our success, and we are confident he will continue to make a positive impact in this expanded role.”

“My three years at Core have been exciting, and I am honored to take on this new role,” said Mike Gayford. “I am privileged to work with such a talented team and look forward to advancing operational excellence, delivering value to our customers, and supporting Core’s long-term growth. Together, we are well positioned to build on our momentum and pursue new opportunities.”

Michael J. Gayford joined the company in March 2023 as Vice President of Operations. Mr. Gayford was promoted to Executive Vice President of Operations in 2025, where he oversaw multi-site manufacturing operations across the United States and Canada, and led the company’s Advanced Manufacturing Engineering and Research and Development Organizations. Mr. Gayford has more than 25 years of experience in engineering, manufacturing, and operational leadership, including more than 17 years in composite manufacturing. Mr. Gayford earned his Bachelor of Science in Mechanical Engineering Technology from Alfred State College.

About Core Molding Technologies, Inc.

Core Molding Technologies is a leading engineered materials company specializing in molded structural products, principally in medium- and heavy-duty truck, powersports, building products, and industrial and utility industries across the United States, Canada, and Mexico. The Company operates in one operating segment as a molder of thermoplastic and thermoset structural products. The Company’s operating segment consists of one reporting unit, Core Molding Technologies. The Company offers customers a wide range of manufacturing processes to fit various program volume and investment requirements. These thermoset processes include compression molding of sheet molding compound (“SMC”), resin transfer molding (“RTM”), liquid molding of dicyclopentadiene (“DCPD”), spray-up and hand-lay-up. The thermoplastic processes include direct long-fiber thermoplastics (“DLFT”) and structural foam and structural web injection molding. Core Molding Technologies serves a wide variety of markets, including the medium and heavy-duty truck, marine, automotive, agriculture, construction, and other commercial products. The demand for Core Molding Technologies’ products is affected by economic conditions in the United States, Mexico, and Canada. Core Molding Technologies’ operations may change proportionately more than revenues from operations.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws that are subject to risks and uncertainties. These statements often include words such as “believe”, “anticipate”, “plan”, “expect”, “intend”, “will”, “should”, “could”, “would”, “project”, “continue”, “likely”, and similar expressions. In particular, this press release may contain forward-looking statements about the Company’s expectations for future periods with respect to its plans to improve financial results, the future of the Company’s end markets. Factors that could cause actual results to differ from those reflected in forward-looking statements relating to our operations and business include: dependence on certain major customers, and potential loss of any major customer due to completion of existing production programs or otherwise; business conditions in the plastics, transportation, power sports, utilities and commercial product industries (including changes in demand for production); the availability and price increases of raw material,; general macroeconomic, social, regulatory and political conditions, including uncertainties surrounding volatility in financial markets; the imposition of new or increased tariffs and the resulting consequences; safety and security conditions in Mexico; costs and other resources related to Core Molding Technologies’ efforts to expand its customer base and grow its business, and provide on-time delivery to customers; ; the Company’s decision to pursue new products and initiatives to quote and execute manufacturing processes for new business, acquire raw materials, address inflationary pressures, regulatory matters and labor relations; the ability to successfully identify, evaluate and manage potential acquisitions and to benefit from and properly integrate any completed acquisitions; the Company’s financial position or other financial information; inadequate insurance coverage to protect against potential hazards; equipment and machinery failure; product liability and warranty claims; cybersecurity incidents or other similar disruptions; and other risks and uncertainties described in the Company’s filings with the SEC. These statements are based on certain assumptions that the Company has made in light of its experience as well as its perspective on historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. Actual results may differ materially from the anticipated results because of certain risks and uncertainties, including those included in the Company’s filings with the SEC. There can be no assurance that statements made in this press release relating to future events will be achieved. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time. All subsequent written and oral forward-looking statements attributable to the Company or persons acting on behalf of the Company are expressly qualified in their entirety by such cautionary statements.

Company Contact:
Core Molding Technologies, Inc.
Alex Panda
Executive Vice President & Chief Financial Officer
apanda@coremt.com

Investor Relations Contact:
Three Part Advisors, LLC
Sandy Martin or Steven Hooser
214-616-2207

Continued purchases and organic accumulation drive approximately 10% growth in SOL holdings since the Company’s August 12 Earnings Update

Quarter-to-date, SOL has outperformed the Nasdaq-100 by 72%, and DFDV has outperformed SOL by 1.4x over that same period

CHAD brings Digital Credit 2.0 to income investors: a 13% annual dividend rate supported by a productive SOL treasury

BOCA RATON, FL, Sept. 28, 2026 (GLOBE NEWSWIRE) — DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first U.S. public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced that it has added approximately 47,706 SOL to its treasury since September 21, 2026, bringing total holdings to approximately 2,538,010 SOL and SOL equivalents worth $309M.

The latest increase represents approximately 2% growth week over week, and brings total SOL and SOL equivalents growth to approximately 10% since the Company’s Q2 earnings report on August 12. With the recently established $300 million CHAD ATM providing an additional source of growth capital, the Company believes its SOL accumulation flywheel is continuing to gain momentum.

“We are building our SOL treasury week by week, and those gains are adding up,” said Joseph Onorati, Chief Executive Officer of DeFi Development Corp. “Our SOL and SOL equivalents grew another 2% last week. Since our Q2 earnings update, we have added over 226,000 SOL, expanding our treasury 10% in just six weeks. With tokenization and agentic AI opening new opportunities for Solana, we intend to keep accumulating and put those holdings to work.”

Building for Tokenization and Agentic AI

DFDV believes tokenization and agentic AI represent significant potential drivers of demand for crypto, with Solana well positioned to support financial activity that requires fast settlement, low transaction costs, and around-the-clock availability.

“Tokenization brings stocks, funds, and other financial assets onchain. Agentic AI introduces software that can transact, make payments, and manage resources on its own,” continued Onorati. “Both need financial infrastructure that operates at lightning speed. We believe Solana will become a core part of that infrastructure, and we intend to keep building our position as that opportunity develops.”

From June 30, 2026 through September 25, 2026, SOL gained approximately 73%, outperforming the Nasdaq-100 by approximately 72 percentage points. DFDV shares gained approximately 105% over the same period, delivering approximately 1.4 times SOL’s percentage return.

“This quarter’s performance has been strong, but our investment thesis in Solana extends much further,” said Onorati. “We see a future with trillions of dollars of assets, payments, and economic activity moving onchain, and we believe Solana will capture a meaningful share of that opportunity. Our objective is to accumulate as much SOL as we can ahead of that adoption, put it to work, and compound our holdings as the network grows.”

CHAD: Bringing Digital Credit 2.0 to More Investors
Alongside continued SOL accumulation, DFDV continued expanding its efforts to build awareness, market access, and liquidity for CHAD, its Nasdaq-listed variable-rate preferred stock. CHAD currently carries a 13% annual dividend rate on its $10 stated amount, equivalent to $1.30 per share annually at the current rate, with dividends paid each business day when declared.

The Company views CHAD as Digital Credit 2.0: preferred equity supported by a productive treasury. Through staking and validator operations, DFDV’s SOL holdings generate recurring rewards and fees, providing an organic source of income to support dividend obligations. Additional SOL deployed into these operations can expand the treasury’s earning capacity, connecting continued accumulation with the economics supporting CHAD.

“Digital Credit 2.0 starts with a simple idea: the assets supporting the preferred should themselves be productive,” said Joseph Onorati, Chief Executive Officer of DeFi Development Corp. “Our SOL treasury earns additional SOL through staking and validator operations. That gives CHAD an income-generating foundation and gives us the opportunity to grow that earning power as we accumulate more.”

“CHAD brings that story to income investors through a 13% annual dividend rate and payments each business day when declared,” continued Onorati. “We want to make CHAD a widely recognized name in digital credit. Expanding investor access, demonstrating dividend coverage, and supporting trading toward its $10 stated amount are priorities for us.”

Learn more about CHAD at www.defidevcorp.com/chad.

For more information, visit defidevcorp.com. To stay up to date with the latest developments and insights, subscribe to our blog.

About DeFi Development Corp.
DeFi Development Corp. (Nasdaq: DFDV) has adopted a treasury policy under which the principal holding in its treasury reserve is allocated to SOL. Through this strategy, the Company provides investors with direct economic exposure to SOL, while also actively participating in the growth of the Solana ecosystem. In addition to holding and staking SOL, DeFi Development Corp. operates its own validator infrastructure, generating staking rewards and fees from delegated stake. The Company is also engaged across decentralized finance (DeFi) opportunities and continues to explore innovative ways to support and benefit from Solana’s expanding application layer.
The Company is also an AI-powered online platform that connects the commercial real estate industry by providing value-add services and software subscriptions to multifamily and commercial property professionals, as the Company connects the increasingly complex ecosystem that stakeholders have to manage. The Company’s data and software offerings are generally offered on a subscription basis as software as a service.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding the anticipated issuance price of shares under the ATM program, the intended use of proceeds, and the Company’s ability to expand its SOL treasury and increase revenue, and can be identified by words such as “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company’s current beliefs, expectations, and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside of the Company’s control. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.

Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) fluctuations in the market price of SOL and any associated losses that the Company may incur as a result of a decrease in the market price of SOL; (ii) a failure for the demand for SOL, or activity on the SOL network, to continue to develop and grow as predicted in our DFDV Model or at all; (iii) volatility in our stock price, including due to future issuances of common stock and securities convertible into common stock; (iv) the effect of and uncertainties related to the ongoing volatility in interest rates; (v) our ability to achieve and maintain profitability in the future; (vi) the impact on our business of the regulatory environment and complexities of complying with such environment, including changes in securities laws or other laws or regulations; (vii) changes in the accounting treatment relating to the Company’s SOL holdings; (viii) our ability to respond to general economic conditions; (ix) our ability to manage our growth effectively and our expectations regarding the development and expansion of our business; (x) our ability to access sources of capital, including debt financing and other sources of capital to finance operations and growth; and (xi) other risks and uncertainties more fully described in the section captioned “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and other reports we file with the SEC.

As a result of these matters, changes in facts, assumptions not being realized, or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

Investor Contact:
ir@defidevcorp.com

Media Contact:
press@defidevcorp.com

• 4D-150 is advancing into Phase 3 development for DME, a second multi-billion-dollar retinal disease market with significant unmet need 
• First patients have been enrolled in 4SIGHT global Phase 3 trial (N=514) evaluating 4D-150 in a treatment-naïve DME population
• Updated 2-year data from SPECTRA Part 1 clinical trial in DME continue to demonstrate a favorable safety profile, durable vision and anatomic improvements and clinically meaningful treatment burden reduction

EMERYVILLE, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT; 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic macular edema (DME). The Company also reported 2-year data from the SPECTRA clinical trial.

“The initiation of 4SIGHT marks an important step in advancing 4D-150 toward becoming a continuous backbone therapy for sustained control of major VEGF-driven retinal diseases,” said David Kirn, M.D., Co-founder, President and Chief Executive Officer of 4DMT. “The favorable safety profile, durable vision and anatomic improvements and clinically meaningful treatment burden reduction observed through two years in the SPECTRA Part 1 clinical trial in DME strengthen our confidence as we expand 4D-150 into the 4SIGHT Phase 3 trial in DME. Following enrollment completion of our two 4FRONT Phase 3 trials in wet AMD, 4SIGHT for DME represents our second Phase 3 program.”

4SIGHT: Phase 3 Trial Design and Regulatory Pathway

4SIGHT is a global Phase 3 multicenter, randomized, double-masked, aflibercept 2 mg (Q8W) comparator-controlled trial of intravitreal 4D-150 in treatment-naïve patients with DME (N=514). All patients will receive five aflibercept loading doses. The primary endpoint is non-inferiority in the mean change from baseline in best corrected visual acuity (BCVA) at Week 52. The key secondary endpoints are treatment burden reduction, comparing the number of aflibercept injections received in the 4D-150 arm versus the aflibercept comparator arm through Week 52, and the proportion of participants with a ≥2-step improvement from baseline in Early Treatment Diabetic Retinopathy Study Diabetic Retinopathy Severity Scale (ETDRS-DRSS) at Week 52. Patients in both arms will be eligible for supplemental aflibercept injections.

Similarly to the 4FRONT Phase 3 wet AMD trials, randomization requires on-trial demonstration of aflibercept responsiveness following the first three of five loading doses during the run-in period (central subfield thickness (CST) ≥10% reduction and ≤400 µm or CST <315 µm).

4D-150 for DME has U.S. Food and Drug Administration (FDA) Regenerative Medicine Advanced Therapy designation, and the Company has alignment with the FDA and the European Medicines Agency on potential Biologics License Application and marketing authorization application filings with the single 4SIGHT Phase 3 DME trial, based on data generated to date for 4D-150 in both the SPECTRA and PRISM clinical trials combined with data from the two Phase 3 clinical trials in the 4FRONT wet AMD program.

“Having treated patients across multiple retinal gene therapy programs over the past decade, including treating the first human patient with 4D-150 nearly five years ago and now enrolling the first patient in 4SIGHT, I believe the initiation of 4SIGHT represents an important milestone for our field,” said Arshad M. Khanani, M.D., M.A., FASRS, Director of Clinical Research at Sierra Eye Associates, Clinical Professor at the University of Nevada, Reno School of Medicine, and Chair of the 4DMT Retina Advisory Board. “In real-world practice, many patients with DME struggle to adhere to the frequent anti-VEGF injection schedule because of the substantial treatment burden and the need for numerous other physician visits, which may contribute to suboptimal visual outcomes. Based on the 2-year data from the SPECTRA trial, I believe a single in-office injection of 4D-150 has the potential to transform the treatment paradigm for DME by providing sustained disease control while reducing treatment burden.”

2-Year Results from SPECTRA Clinical Trial (Data Cutoff of March 12, 2026):

• Safety Results (N=22):
  • 4D-150 was well tolerated, with no intraocular inflammation at any timepoint
  • No ocular serious adverse events
  • No hypotony, endophthalmitis, vasculitis, choroidal effusions or retinal artery occlusions
  • No progression to proliferative diabetic retinopathy or vitreous hemorrhage
• Clinical Activity Results for Phase 3 Dose (3E10 vg/eye, n=9):
  • Mean gain in BCVA of +10.8 letters
  • Mean reduction in CST of -176 µm, as measured by optical coherence tomography
  • Supplemental Injections:
    • Utilized stringent supplemental criteria to maximize patient safety while assessing initial clinical activity
    • Post-aflibercept loading doses (3), patients required substantially fewer injections compared to on-label aflibercept 2mg Q8W:
      • 61% overall treatment burden reduction (5.2 mean supplemental injections per patient vs. 13.0 injections projected with on-label aflibercept 2 mg Q8W)
      • 75% estimated overall treatment burden reduction utilizing 4SIGHT Phase 3 supplemental injection criteria, which are more in line with contemporary Phase 3 trials (3.2 estimated mean supplemental injections per patient vs. 13.0 injections projected with on-label aflibercept 2 mg Q8W; retrospective estimate, actual results in 4SIGHT may differ)
      • 2 of 9 (22%) remained injection-free

Additional details on the SPECTRA data and 4SIGHT clinical trial design can be found in our corporate deck on our Investor Relations website.

About 4D-150

4D-150 is a potential continuous backbone therapy designed to provide multi-year, and potentially lifelong, sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) within the retina following a single intravitreal injection. 4D-150 utilizes our customized and primate-evolved intravitreal AAV vector (R100), which was invented at 4DMT through our proprietary Therapeutic Vector Evolution platform, as well as a proprietary transgene payload designed for robust aflibercept expression plus an anti-VEGF-C inhibitory RNA. 4D-150 is being developed for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), which each affect millions of patients globally, with the goal of freeing patients from burdensome injections while preserving vision.

About DME

DME, or diabetic macular edema, is a complication of diabetic retinopathy and is a highly prevalent disease with significant unmet medical need and poor treatment adherence. It is estimated that there are approximately one million individuals with DME in the U.S., according to published data. DME is characterized by inflammation and swelling in the macula due to leakage from blood vessels, which can lead to vision loss. DME is typically treated with intravitreal anti-VEGF agents administered approximately every 4-12 weeks, although patient compliance with therapy is poor and results in high unmet medical need.

About 4DMT

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate, 4D-150, is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration and the second indication is diabetic macular edema, which are both in Phase 3 development. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, Backbone 4 Retina™ and the 4DMT logo are trademarks of 4DMT.  

All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied.

Learn more at www.4DMT.com and follow us on LinkedIn.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the therapeutic potential, treatment-burden reduction, durability and clinical benefits of, the potential market for, as well as the plans, announcements and related timing for the clinical development, regulatory interactions, and potential commercialization of our product candidates, including 4D-150. The words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target,” and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including risks and uncertainties that are described in greater detail in the section entitled “Risk Factors” in 4D Molecular Therapeutics’ most recent Quarterly Report on Form 10-Q, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent 4D Molecular Therapeutics’ views only as of today and should not be relied upon as representing its views as of any subsequent date. 4D Molecular Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Contacts:

Media:
Jenn Gordon
dna Communications
Media@4DMT.com

Investors:
Julian Pei
Head of Investor Relations and Strategic Finance
Investor.Relations@4DMT.com

Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression and retained HER2-positive disease

Subgroup analyses support CD47 expression as a predictive biomarker

ASPEN-06 clinical findings further validate Company’s biomarker-driven development strategy and reinforce its continued advancement in the ongoing Phase 2 ASPEN-09-Breast clinical trial

On track for mid-2027 topline data readout from 80 patients in Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc. (“ALX Oncology”; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced the publication of clinical data from its ASPEN-06 randomized Phase 2 clinical trial in Nature Medicine.

The Nature Medicine publication, titled “Evorpacept plus trastuzumab, ramucirumab and paclitaxel in HER2-positive gastric cancer: a randomized phase 2 trial” can be accessed here. The data demonstrated that the Company’s investigational CD47-blocker, evorpacept, generated encouraging efficacy with manageable safety among patients with previously treated HER2-positive advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer.

“Publication of our ASPEN-06 data in Nature Medicine, a prestigious peer-reviewed scientific journal, further validates the clinical potential of evorpacept and reinforces our biomarker-driven development strategy,” said Barbara Klencke, M.D., Chief Medical Officer of ALX Oncology. “Data from ASPEN-06 demonstrated that patients whose tumors retained HER2 expression and had high CD47 expression experienced the greatest benefit from evorpacept-based therapy, supporting our hypothesis that evorpacept can enhance the activity of HER2-directed treatment regimens and highlights CD47 expression as a potential predictive biomarker. These findings further strengthen our conviction in the ongoing Phase 2 ASPEN-09-Breast clinical trial in HER2-positive metastatic breast cancer, which remains on track for a topline data readout from 80 patients in mid-2027.”

The ASPEN-06 clinical trial (NCT05002127) was a randomized Phase 2 (open-label)/3 (blinded), international, multi-center study, that evaluated evorpacept in combination with HERCEPTIN^® (trastuzumab), CYRAMZA^® (ramucirumab) and paclitaxel (TRP) compared with TRP alone (control), for patients with metastatic second- or third-line HER2 overexpressing GC/GEJ adenocarcinoma who have progressed on or after prior HER2-directed therapy and fluoropyrimidine- or platinum-containing chemotherapy, and who were suitable for chemotherapy. One hundred twenty-seven adult patients were enrolled in the Phase 2 portion of the study.

Results demonstrated that evorpacept plus TRP achieved an objective response rate (ORR) of 40.3% compared with 26.6% for TRP alone in the intent-to-treat (ITT) population. Among patients with retained HER2-positive disease, based either on a fresh tumor biopsy or ERBB2 gene amplification detected in circulating tumor DNA (ctDNA), ORR increased to 48.9% versus 25.0% for the control arm.

Post-hoc biomarker analyses demonstrated CD47 expression as a potential predictive biomarker for evorpacept. Among patients with retained HER2-positive disease and elevated CD47 expression (≥5% CD47 IHC3+ staining), evorpacept plus TRP achieved an ORR of 63.6% compared with 23.1% for TRP alone, with improvements in median progression-free survival (PFS) to 19.5 months versus 7.0 months and median duration of response (DOR) of 25.5 versus 8.4 months, supporting further evaluation of CD47-guided patient selection in future studies.

In conclusion, findings from the randomized Phase 2 portion of the ASPEN-06 study suggest that evorpacept in combination with TRP may provide meaningful clinical benefit as a second- or third-line treatment for patients with GC or GEJ cancer with retained HER2 expression. Post-hoc analyses further suggest that this benefit may be enhanced in patients with high CD47 expression, supporting the proposed mechanism that both retained HER2 expression and elevated CD47 levels may be important drivers of efficacy through enhanced antibody-dependent cellular phagocytosis. Given the Company’s disciplined focus and resource allocation priorities, ALX Oncology elected to not pursue a U.S. registrational path with a Phase 3 trial in GC and will consider exploring development partnerships to advance this program in gastric cancer. Importantly, findings from the ASPEN-06 study further validate the Company’s biomarker-driven development approach and support the ongoing Phase 2 ASPEN-09-Breast trial (NCT07007559) evaluating evorpacept in combination with trastuzumab and chemotherapy in patients with HER2-positive metastatic breast cancer, with topline data from 80 patients expected in mid-2027.

HERCEPTIN^® and CYRAMZA^® are the registered trademarks of their respective owners.

About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action. A Phase 1, dose-escalation trial of ALX2004 is ongoing in patients with EGFR-expressing solid tumors. More information is available at www.alxoncology.com and on LinkedIn and X.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements regarding future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, such as the ongoing Phase 2 ASPEN-09-Breast clinical trial in HER2-positive metastatic breast cancer, research and development costs, regulatory approvals, timing and likelihood of success, plans and objects of management for future operations, as well as statements regarding industry trends. Such forward-looking statements are based on ALX Oncology’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause ALX Oncology’s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These and other risks are described more fully in ALX Oncology’s filings with the Securities and Exchange Commission (“SEC”), including ALX Oncology’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents ALX Oncology files with the SEC from time to time. Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Relations Contact:
Kevin Lui
Director, Investor Relations
kevin.lui@precisionaq.com

Media Contact:
Genevieve Britton
Senior Director, Public Relations
genevieve.britton@precisionaq.com

Company holds exclusive access to imaging data from 2,100+ U.S. hospitals through its ongoing data partnership with vRad, the largest teleradiology provider in the United States

BOSTON, Sept. 28, 2026 (GLOBE NEWSWIRE) — GuideAI Health Corp. (Cboe CA: GDAI) (FSE: ZN0) (“GuideAI” or the “Company“) is pleased to announce the renewal of its data exclusivity agreement with vRad (Virtual Radiologic), which aims to develop artificial intelligence models for the detection and characterization of multiple vascular diseases. The renewed collaboration provides GuideAI with exclusive access to imaging data from more than 2,100 hospitals across the United States, which the Company believes to be one of the largest and most diverse real-world imaging datasets of its kind.

Under the renewed partnership, GuideAI retains exclusive rights to develop AI models using de-identified imaging data generated across vRad’s national network of more than 2,100 hospitals and healthcare facilities. GuideAI’s technology is currently deployed within the workflow of vRad’s approximately 500 radiologists, where it supports the identification of vascular disease at the point of care.

The scale and diversity of vRad’s dataset provide GuideAI with a durable foundation on which to train and validate its algorithms. Building on its work in peripheral arterial disease, the Company intends to expand its platform to the detection and characterization of multiple vascular diseases, with the goal of surfacing disease earlier and supporting more precise, more comprehensive treatment decisions for patients nationwide.

GuideAI Health CEO, Raj Shah, commented, “Renewing our exclusive data collaboration with vRad is a defining moment for GuideAI. Access to imaging data from more than 2,100 hospitals, combined with the trust of the 500 radiologists who already have access to our technology in their daily workflow, gives us an exceptional foundation to build clinically meaningful AI, furthering our aim of helping clinicians catch disease earlier and improve outcomes for patients.”

About GuideAI Health Corp.

GuideAI Health Corp. is a healthcare technology company using artificial intelligence to enable the early detection of vascular disease and support more precise treatment decisions. Its platform analyzes routine CT scans to identify peripheral vascular disease. By surfacing disease earlier, GuideAI aims to improve patient outcomes while helping hospitals and radiology groups deliver more comprehensive vascular care.

For more information, please visit www.guideaihealth.com.

On Behalf of the Board of Directors:

Raj Shah

CEO

Contact:

Phone: (416) 309-3583
Email: info@guideaihealth.com

Cautionary Note Regarding Forward-Looking Statements

This news release contains certain “forward-looking statements” and “forward-looking information” within the meaning of applicable Canadian securities laws (collectively, “forward-looking information”). Forward-looking information in this news release includes, but is not limited to, statements regarding: the continuation and anticipated benefits of the Company’s renewed data exclusivity agreement and collaboration with vRad; the Company’s continued exclusive access to, and ability to use, de-identified imaging data generated across vRad’s network; the scope, scale, diversity and anticipated value of that dataset; the continued deployment and use of GuideAI’s technology within vRad’s radiology workflow; the Company’s ability to train, develop, validate and commercialize artificial intelligence models for the detection and characterization of vascular diseases; the expansion of the Company’s platform beyond peripheral arterial disease; the potential for the Company’s technology to identify disease earlier, support more precise and comprehensive treatment decisions and improve patient outcomes; and the Company’s business plans, objectives and future activities. Forward-looking information is often, but not always, identified by words or phrases such as “anticipates”, “believes”, “expects”, “intends”, “plans”, “aims”, “goal”, “may”, “will”, “would”, “could”, “should”, “potential”, “continue” and similar expressions. 

Forward-looking information is based on management’s estimates, assumptions and expectations as of the date of this news release, including assumptions regarding: the continued validity and enforceability of, and performance by the parties under, the renewed agreement; the Company’s continued ability to access and lawfully use sufficient quantities of de-identified imaging data; the quality, completeness, diversity and representativeness of the available data; the continued availability, performance and integration of the Company’s technology within vRad’s workflow; the Company’s ability to retain qualified personnel, secure required financing and other resources, protect its intellectual property and data rights, and complete development, testing and validation activities; and the receipt of any required regulatory, clinical, commercial or third-party approvals. Although the Company considers these assumptions reasonable, they may prove to be incorrect. 

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied, including risks relating to: the termination, non-renewal, amendment, breach or unenforceability of the renewed agreement; interruptions, restrictions or loss of access to imaging data or the vRad network; limitations in the quantity, quality, completeness, diversity or representativeness of available data; privacy, data protection, cybersecurity, data de-identification, consent and regulatory compliance; the accuracy, reliability, generalizability, validation and clinical utility of artificial intelligence models; development delays, technical failures, integration challenges and the inability to achieve expected performance or commercial objectives; changes in laws, regulations, standards of care or regulatory requirements applicable to artificial intelligence, medical devices, healthcare or data use; failure to obtain or maintain required approvals; intellectual property disputes and the inability to protect proprietary rights; competition and technological change; dependence on key personnel, collaborators, service providers and third parties; the availability of capital and other resources; and the possibility that the anticipated clinical, operational or commercial benefits of the collaboration and the Company’s technology will not be realized. Additional risks are described in the Company’s public disclosure documents available under its profile on SEDAR+ at www.sedarplus.ca. Readers are cautioned not to place undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. 

Jacopo Barontini and Fulvio Taglialatela Strengthen Support for Italian Companies and Creditors Facing Complex Restructuring, Turnaround and Cross-Border Challenges

MILAN, Sept. 28, 2026 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Jacopo Barontini as a Senior Managing Director and Head of Turnaround & Restructuring in Italy, joined by Fulvio Taglialatela as a Managing Director, both in the firm’s Corporate Finance segment in Milan. They will support companies and creditors through complex domestic and cross-border restructuring and turnaround situations.

“Businesses and capital providers in Italy face growing financial and operational pressures due to higher costs, subdued growth and continued economic uncertainty,” said Emanuele Grasso, Italy Leader and Head of Italy Corporate Finance at FTI Consulting. “Jacopo and Fulvio bring deep experience advising clients through critical situations and developing solutions that preserve value. Their arrival reflects our ongoing investment in our capabilities and significantly strengthens our ability to support the restructuring needs of businesses and creditors, from stabilising operations and liquidity to negotiating capital structures and delivering sustainable turnarounds.”

Mr. Barontini brings more than 30 years of experience in restructuring, corporate finance, distressed M&A and special situations, with a focus on financial restructurings, performance improvement and turnaround management. He has advised companies, creditors and investors on domestic and cross-border, in-court and out-of-court matters across a broad range of industries. Mr. Barontini is also a qualified Italian chartered accountant.

Prior to joining FTI Consulting, Mr. Barontini was Head of Financial Restructuring and Co-Head of Financial & Operational Restructuring in Italy at Alvarez & Marsal. He was previously a Partner at Deloitte.

Mr. Taglialatela has more than 20 years of experience in financial restructuring, turnaround and debt restructuring advisory for clients in the real estate, hospitality, consumer products, automotive and energy sectors. He has advised companies, creditors and investors on restructuring transactions, business reviews, debt advisory matters and turnaround situations. Mr. Taglialatela is also a qualified Italian chartered accountant and auditor. Before joining FTI Consulting, Mr. Taglialatela was a Senior Director at Alvarez & Marsal. He previously worked at Deloitte and PwC.

Diederick van der Plas, EMEA Co-Chair and EMEA Head of the Corporate Finance segment at FTI Consulting, added, “Jacopo and Fulvio are well established in Italy’s restructuring market, with strong relationships across the country’s business and financial community. Their arrival strengthens our ability to take on larger and more complex mandates in Italy, as well as cross-border engagements when clients’ needs extend beyond the domestic market. We look forward to building on these appointments to establish FTI Consulting as a leading restructuring adviser in Italy, giving clients access to the full strength of our global practice.”

Commenting on his appointment, Jacopo Barontini said, “FTI Consulting’s independence, collaborative culture and dedicated global restructuring and distress-related capabilities were key to my decision to join. I look forward to building the team in Italy with Fulvio and colleagues who share my commitment to helping clients achieve the best possible outcomes in stressed and distressed situations.”

Mr. Taglialatela added, “Companies facing financial distress need practical advice, decisive action and solutions that deliver tangible results. That approach has guided my work throughout my career. FTI Consulting’s global restructuring capabilities provide a strong platform to apply that approach, and I am excited to work with Jacopo to grow the practice in Italy.”

The appointments of Mr. Barontini and Mr. Taglialatela follow the recent addition of Dr. Riccardo Siliprandi in the Milan office to lead FTI Consulting’s Energy practice in Italy.

FTI Consulting’s Restructuring team in Italy works with companies, boards, investors, lenders and other stakeholders facing financial or operational pressure. It helps clients improve performance and cash flow, assess the state of a business, manage insolvency proceedings and execute turnaround plans.

About FTI Consulting
FTI Consulting, Inc. is a leading global expert firm for organisations facing crisis and transformation, with more than 8,100 employees located in 32 countries and territories as of June 30, 2026. In certain jurisdictions, FTI Consulting’s services are provided through distinct legal entities that are separately capitalised and independently managed. The Company generated $3.8 billion in revenues during fiscal year 2025. More information can be found at www.fticonsulting.com.

FTI Consulting, Inc.
200 Aldersgate
Aldersgate Street
London, EC1A 4HD

Investor Contact:                                
Mollie Hawkes
+1.617.747.1791
mollie.hawkes@fticonsulting.com

Media Contact:                                
publicrelations@fticonsulting.com

CINCINNATI, Sept. 28, 2026 (GLOBE NEWSWIRE) — Phillips Edison & Company, Inc. (Nasdaq: PECO) (“PECO” or the “Company”), one of the nation’s largest owners and operators of high-quality, grocery-anchored neighborhood shopping centers, will announce its Third Quarter 2026 earnings results on Monday, October 26, 2026, after the market closes. PECO’s earnings release and financial supplement will be posted on the Investor Relations section of the Company’s website at https://investors.phillipsedison.com/. Chairman and Chief Executive Officer Jeff Edison, President Bob Myers and Chief Financial Officer John Caulfield will host an earnings conference call, which will also be webcast, on Tuesday, October 27, 2026, at 12:00 p.m. ET.

Third Quarter 2026 Earnings Conference Call and Webcast Details:

• Date: Tuesday, October 27, 2026
• Time: 12:00 p.m. Eastern Time
• Participant Toll-Free Dial-In Number: (800) 715-9871
• Participant Toll Dial-In Number: (646) 307-1963
• Conference ID: 4551083
• Webcast: Third Quarter 2026 Webcast Link

A webcast replay will be available approximately one hour after the conclusion of the event using the same link. Webcasts are archived on PECO’s Investor Relations website.

Connect with PECO
For additional information, please visit https://www.phillipsedison.com/
Follow PECO on:
X at https://x.com/PhillipsEdison
LinkedIn at https://www.linkedin.com/company/phillipsedison&company

About Phillips Edison & Company
Phillips Edison & Company, Inc. (“PECO”) is one of the nation’s largest owners and operators of high-quality, grocery-anchored neighborhood shopping centers. Founded in 1991, PECO has generated strong results through its vertically-integrated operating platform and national footprint of well-occupied shopping centers. PECO’s centers feature a mix of national and regional retailers providing necessity-based goods and services in fundamentally strong markets throughout the United States. PECO’s top grocery anchors include Kroger, Publix, Albertsons and Ahold Delhaize. As of June 30, 2026, PECO managed 330 shopping centers, including 302 wholly-owned centers comprising 33.9 million square feet across 31 states and 28 shopping centers owned in three institutional joint ventures. PECO is focused on creating great grocery-anchored shopping experiences and improving communities, one neighborhood shopping center at a time.

PECO uses, and intends to continue to use, its Investors website, which can be found at https://investors.phillipsedison.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. 

Investors:
Kimberly Green, Head of Investor Relations
(513) 692-3399, kgreen@phillipsedison.com

Newtek Advantage® Integrates Banking, Payments, Payroll and Business Information into a More Connected Customer Experience

BOCA RATON, Fla., Sept. 28, 2026 (GLOBE NEWSWIRE) — NewtekOne, Inc. (NASDAQ: NEWT) (“NewtekOne” or the “Company”) announced today that its bank subsidiary, Newtek Bank, N.A. (“Newtek Bank”), has expanded connectivity between Newtek Bank accounts and the accounting and business applications independent business owners rely on to manage their businesses. Newtek Bank now integrates with Sage, Xero, FreshBooks, Restaurant365 and other leading applications, building on its existing connectivity with QuickBooks and broadening the digital ecosystem available through Newtek Advantage^®.

This expanded connectivity is designed to make business banking integrated with the systems customers already use to track financial performance, reconcile transactions and manage day-to-day operations. By connecting with QuickBooks, Sage, Xero and FreshBooks, Newtek Bank can integrate with accounting platforms representing approximately 85% of the U.S. small-business accounting software market. Additional supported applications include 1-800Accountant, Expensify, AppFolio, BILL and others.

Newtek Advantage^®, the Company’s internally developed and patent-pending online business portal, serves as the central customer experience for Newtek Bank and NewtekOne’s broader suite of business solutions. Through Newtek Advantage^®, independent business owners can access their Newtek Bank relationship, view banking information, monitor real-time payment activity and connect more of their financial data in a single portal.

The enhanced application connectivity complements NewtekOne’s integrated approach to business financial services. Customers using Newtek Real-Time Payment Solutions can accept credit card, debit card and ACH payments, with merchant processing proceeds settling directly into their Newtek Bank account the same day, seven days a week, 365 days a year. Customers using Newtek Payroll have the ability to fund and execute payroll the same day. Together, these capabilities help connect transactional banking, payments and payroll information with many of the accounting and business applications customers use to operate their businesses.

Barry Sloane, Chairman, President and Chief Executive Officer of NewtekOne, commented, “Independent business owners increasingly expect their bank to work inside the digital systems they use to run their businesses. By expanding Newtek Bank’s connectivity with QuickBooks, Sage, Xero, FreshBooks, Restaurant365 and other applications, we are making banking information more connected to our customers’ daily workflows.”

“The Newtek Advantage^® brings more of the customer relationship into one connected experience. Business owners can access banking information, view real-time payment activity, settle merchant processing proceeds directly into Newtek Bank, fund and execute payroll the same day and connect all of that information with the accounting and business applications they already use. We believe this is an important step in advancing connected business banking for independent business owners.”

“These capabilities also complement Newtek Zero-Fee Business Banking™, which is truly a ‘no fee’ bank account — no monthly service fees, no transaction fees, no ACH fees, no wire fees, no overdraft fees and no minimum balance requirement — that also pays a competitive rate of interest on checking balances.”

Mr. Sloane concluded, “We have built a differentiated, technology-enabled financial services ecosystem that helps independent business owners grow revenue, reduce expense, and reduce risk.”

About NewtekOne, Inc.

NewtekOne^®, Your Business Solutions Company^®, is a financial holding company, which along with its bank and non-bank consolidated subsidiaries (collectively, “NewtekOne”), provides a wide range of business and financial solutions under the Newtek^® brand to independent business owners. Since 1999, NewtekOne has provided state-of-the-art, cost-efficient products and services and efficient business strategies to independent business owners across all 50 states to help them grow their sales, control their expenses, and reduce their risk.

NewtekOne’s and its subsidiaries’ business and financial solutions include: Banking (Newtek Bank, N.A.), Business Lending, SBA Lending Solutions, Electronic Payment Processing, Accounts Receivable Financing & Inventory Financing, Insurance Solutions and Payroll and Benefits Solutions. In addition, NewtekOne offers its clients the Technology Solutions (Cloud Computing, Data Backup, Storage and Retrieval, IT Consulting and Web Services) provided by Intelligent Protection Management Corp. (IPM.com)

Newtek^®, NewtekOne^®, Newtek Bank^®, National Association, Your Business Solutions Company^®, One Solution for All Your Business Needs^® and Newtek Advantage® are registered trademarks of NewtekOne, Inc.

Note Regarding Forward-Looking Statements
Certain statements in this press release are “forward-looking statements” within the meaning of the rules and regulations of the Private Securities Litigation Reform Act of 1995 and are based on the current beliefs and expectations of NewtekOne’s management and are subject to significant risks and uncertainties. Actual results may differ materially from those set forth in the forward-looking statements. See “Note Regarding Forward-Looking Statements” and the sections entitled “Risk Factors” in our filings with the Securities and Exchange Commission, which are available on NewtekOne’s website (https://investor.newtekbusinessservices.com/sec-filings) and on the Securities and Exchange Commission’s website (www.sec.gov). Any forward-looking statements made by or on behalf of NewtekOne speak only as of the date they are made, and NewtekOne does not undertake to update forward-looking statements to reflect the impact of circumstances or events that arise after the date the forward-looking statements were made.

SOURCE: NewtekOne, Inc.

Investor Relations & Public Relations
Contact: Bryce Rowe
Telephone: (212) 273-8292 / browe@newtekone.com